Bioverativ USA Inc.

True North Therapeutics, Inc.

Vega Therapeutics, Inc.

Genzyme Corporation

Electra Therapeutics, Inc.

Sandip Panicker

Graham Parry

Nancy E Stagliano

Peter Van Vlasselaer

Adam David Rosenthal

Tony Sang Young Byun

Tony SangYoung Byun

Karen Sue Christopherson

Quehuong Thi Dong

Stephen James Moore

Pavel A Nikitin

Tony Byun

Eileen Lingshu Rose

Provided here are antibodies that bind Protein S, and methods of making and using such antibodies. In some embodiments, the Protein S antibodies provided herein are useful for treating a bleeding disorder or platelet disorder, or a condition characterized by reduced or impaired blood coagulation and/or clotting.

Protein S antibodies, methods of making and uses thereof

The present disclosure provides antibodies that specifically bind complement pathway component C1s The present disclosure provides nucleic acids comprising nucleotide sequences encoding the anti-C1s antibodies; and host cells comprising the nucleic acids. The present disclosure provides compositions comprising the anti-C1s antibodies. The present disclosure provides methods of use of the anti-C1s antibodies.

Anti-C1S antibodies and methods of use thereof

The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.

Anti-complement C1s antibodies and uses thereof

The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. In some embodiments, such anti-complement C1s antibodies inhibit proteolytic activity of C1s. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.

Provided herein are antibodies that bind signal regulatory protein gamma (SIRPγ), as well as SIRPα and/or SIRPβ1, and methods of using such antibodies (referred to as SIRP antibodies). In some embodiments, the SIRP antibodies are human monoclonal antibodies that bind human SIRPγ as well as SIRPα and/or SIRPβ1. In some embodiments, the SIRP antibodies provided herein are useful for treating a disease or condition associated with overactivation and/or hyperproliferation of lymphocytes, myeloid cells, or a combination thereof, or a disease or condition associated with SIRPα, SIRPβ1 and/or SIRPγ activity.

SIRP α, SIRP β 1, and SIRP γ antibodies and uses thereof

The present disclosure provides anti-complement factor Bb antibodies, and compositions comprising the antibodies. The anti-Bb antibodies are useful for treating complement-mediated disorders. The present disclosure provides methods of treating complement-mediated disorders.

Anti-complement factor Bb antibodies and uses thereof

The present disclosure provides humanized anti-C1s antibodies. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the humanized anti-C1s antibodies; and host cells comprising the nucleic acids. The present disclosure provides compositions comprising the humanized anti-C1s antibodies. The present disclosure provides methods of use of the humanized anti-C1s antibodies.

Polynucleotides encoding anti-C1s antibodies

The present disclosure provides methods of inducing a complement activity on a surface of a cell comprising contacting the cell with an effective amount of an anti-Factor B antibody, wherein the anti-Factor B antibody inhibits dissociation of a C3bBb complex into a Factor Bb and a C3b.

Growing community of inventors

South San Francisco, CA, United States of America

Sandip Panicker